INSIGHTS ON CLINICAL TRIAL DESIGN

• Clinical Trial Evaluation And Referral Challenging For Physicians

  Physicians often encounter information gaps when evaluating clinical trials for patients. A recent survey indicates a fragmented, confusing trial information landscape that is difficult to navigate.

• What Clinical Trial Decision Makers Are Prioritizing In 2025

  In 2025, clinical trial operations are undergoing a transformative shift driven by the need for speed, cost-efficiency, and patient-centered approaches.

• The New Era Of Project Optimus: Implications For Oncology

  In this presentation, expert speakers bring the impact of Project Optimus to life through real-world case studies and practical examples.

• Why Early Device Decisions Matter: How Immunovant Accelerated Its Program

  Deferring autoinjector selection can seem to preserve flexibility, yet it often moves constraints downstream. Integrating the device during Phase IIb changed one program's timeline and removed bridging work.

• Executing Concurrent Decentralized RCTs And RWE At Scale

  3/31/2026

  See how a team of four managed data for 40 peer-reviewed studies and 200,000 participants.

• A New Blueprint For Transforming Feasibility And Recruitment

  9/22/2025

  Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.

• Site Networks And Hybrid Solutions

  7/22/2025

  Learn how community- and patient-centric site networks that have DCT capabilities are able to work with a broad-range of site types.

• Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

  9/25/2025

  The Bayesian Logistic Regression Model (BLRM) is redefining Phase I clinical trial design by bringing flexibility, precision, and patient-centered safety into early drug development.

• Assessing Diversity In Early-Phase Clinical Trials In A Rapidly Changing Regulatory Environment

  5/5/2025

  Learn more about structuring early-phase trials to address population variation and the contributing factors to safe drug administration, both of which are essential to a drug development plan.